ArticleTranslational pediatrics2026
Gamma-aminobutyric acid supplementation combined with gonadotropin-releasing hormone analog therapy versus gonadotropin-releasing hormone analog therapy alone for linear growth in children with growth retardation: a retrospective cohort study.
Article in Translational pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Growth retardation is a significant clinical challenge in children receiving gonadotropin-releasing hormone agonist (GnRHa) therapy. This study aimed to evaluate whether gamma-aminobutyric acid (GABA) supplementation combined with GnRHa therapy improves growth outcomes in children experiencing growth retardation during GnRHa treatment. Methods: This single-center retrospective cohort study included 150 pediatric patients with CPP or EFP (mean age 9.0 years, 83.3% female) who showed growth retardation [growth velocity (GV) <5 cm/year] despite adequate GnRHa suppression of hormone levels. The intervention group (n=99) received 100 mg of gamma-aminobutyric acid (GABA) orally before bedtime in addition to standard GnRHa therapy, while the control group (n=51) received GnRHa alone. Baseline covariates, including age, height standard deviation score (HtSDS), bone age/chronological age (BA/CA) ratio, sex, target height, growth velocity (GV), insulin-like growth factor-1 (IGF-1) levels, and duration of prior GnRHa treatment, were collected from medical records at enrollment using standardized chart review protocols. Follow-up assessments were conducted at 3, 6, and 12 months. The primary outcome was the change in height standard deviation score (ΔHtSDS) after 12 months. Secondary outcomes included GV, predicted adult height (PAH), and adverse events (AE). Differences between groups were analyzed using Welch's Results: A total of 150 children were enrolled. Baseline characteristics were well balanced between groups (mean age: 9.0 Conclusions: GABA supplementation was associated with safe and significant improvements in linear growth in children with growth retardation during GnRHa therapy, providing a potentially practical adjunctive treatment for this clinical challenge.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.